来凯医药-B尾盘涨超13% LAE102的I期SAD研究结果可观 与礼来合作有望增强国际影响力

智通财经
Jun 09, 2025

来凯医药-b(02105)尾盘涨超13%,截至发稿,涨13.05%,报22港元,成交额2.41亿港元。中信建投发布研报称,来凯医药核心产品LAE102是自主研发针对ActRIIA的单克隆抗体,通过阻断Activin-ActRII通路促进肌肉再并减少脂肪,可与GLP-1协同作用以实现高质量体重管理。2024年11月20日,公司发布公告,与礼来就LAE102针对肥胖症治疗在美国开展临床合作;今年3月...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10